Stefan Borgwardt
Chair of Psychiatry and Psychotherapy at the University of Lübeck
Data updated
Research Footprint
Stefan Borgwardt appears in 23 tracked papers (2015–2026), most studied alongside LSD, MDMA and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: Acute effects of lysergic acid diethylamide in healthy subjects (424 citations).
Frequent co-authors: Matthias Liechti, Felix Müller and Lukas Ley.
Publication Landscape
How the 23 papers Blossom tracks for Stefan Borgwardt line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Stefan Borgwardt's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 23 of 23 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Stefan Borgwardt publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Stefan Borgwardt publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Stefan Borgwardt is a prominent German psychiatrist whose research utilizes structural and functional neuroimaging to understand the effects of psychoactive drugs on the brain. His team explores the early phases of psychosis and evaluates the efficacy of cannabinoids and psychedelics in treating major depression and schizophrenia, integrating genetic and computational modeling into clinical care.
Key Impact
Researches neurofunctional mechanisms of innovative treatments like cannabinoids and psychedelics for psychosis and depression.
Collaboration Network
21 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Stefan Borgwardt's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Stefan Borgwardt is associated with.
King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →